This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

OrbusNeich File Patent Infringement Lawsuit Against Boston Scientific In Ireland

FORT LAUDERDALE, Fla., March 8, 2013 /PRNewswire/ -- OrbusNeich Medical Inc. and its subsidiary, Orbus International B.V., (collectively, "OrbusNeich") today announced that they have commenced a patent infringement lawsuit in Ireland against Boston Scientific Corporation (NYSE: BSX) and two of its Irish subsidiaries (collectively, "Boston Scientific").

The lawsuit alleges that Boston Scientific are infringing two European patents covering certain novel stent designs.  The two patents, held by OrbusNeich, are designated EP 2 311 412 and EP 1 341 482.  OrbusNeich allege that the patents are infringed by a number of Boston Scientific's coronary stent systems, including the "PROMUS Element™", "PROMUS Element Plus™", "OMEGA™", "TAXUS™", "SYNERGY™", and "Promus PREMIER™" lines of stents.

OrbusNeich are seeking damages for the infringement and an injunction prohibiting Boston Scientific from manufacturing, offering for sale, marketing or stocking products that infringe the patents in Ireland.

Al Novak, Chairman and Chief Executive Officer of OrbusNeich, said, "The lawsuit in Ireland is a continuation of our efforts to protect and enforce our intellectual property rights. We intend to vigorously pursue these efforts to prevent unlawful competitive practices and protect our unique technologies throughout the world."

On February 20, 2013, OrbusNeich commenced patent infringement actions in Germany and the Netherlands against Boston Scientific and its distribution affiliates in those countries.  

On February 11, 2013, OrbusNeich received a favorable ruling from the European Patent Office (EPO) in connection with EP 1 341 482, one of the two patents asserted against Boston Scientific in these lawsuits. The EPO upheld the validity of claim 1 of the '482 patent, as amended, over an opposition filed by Boston Scientific and Terumo Kabushiki Kaisha.  The EPO found that claim 1 of the '482 patent met all requirements of the European Patent Convention, and that the stents covered by the claim were novel and inventive over the prior art.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Azule™, R stent™, Scoreflex™, Sapphire™, Sapphire II™ and Sapphire NC™. Development stage products include the COMBO Dual Therapy Stent™, the world's first dual therapy stent. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

SOURCE OrbusNeich

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,128.85 +77.12 0.45%
S&P 500 1,985.31 +11.68 0.59%
NASDAQ 4,460.0840 +35.38 0.80%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs